Niagen Bioscience (NAGE) Retained Earnings (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Retained Earnings of $240.5 million for Q1 2026, up 3.6% year-over-year from $232.1 million in Q1 2025, and little changed quarter-over-quarter from $241.0 million in Q4 2025.
Niagen Bioscience (NAGE) Retained Earnings (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Retained Earnings for 14 consecutive years, with $240.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 3.6% year-over-year to $240.5 million; the TTM figure through Mar 2026 stood at $240.5 million (up 3.6% YoY), while the FY2025 annual figure was $241.0 million, up 232.48% from the prior year.
- Retained Earnings steadied at $240.5 million in Q1 2026 per NAGE's latest filing, from $241.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $241.0 million in Q4 2025 and bottomed at -$191.0 million in Q1 2024.
- Historically, Retained Earnings has averaged $56.6 million across 5 years, with a median of $214.1 million in 2022.
- Annual changes were most pronounced in 2023 — Retained Earnings sank 193.04% — and 2025, when it surged 232.48%.
- Niagen Bioscience's Retained Earnings stood at $214.1 million in 2022, then grew by 2.22% to $218.8 million in 2023, then slumped by 183.12% to -$181.9 million in 2024, then soared by 232.48% to $241.0 million in 2025, then fell by 0.22% to $240.5 million in 2026.
- Business Quant data shows NAGE's Retained Earnings at $240.5 million in Q1 2026, $241.0 million in Q4 2025, and $239.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 239.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.70 Mn |
| Mar 31, 2026 | 240.46 Mn |
| Dec 31, 2025 | 240.99 Mn |
| Sep 30, 2025 | 239.27 Mn |
| Jun 30, 2025 | -173.24 Mn |
| Mar 31, 2025 | 232.12 Mn |
| Dec 31, 2024 | -181.91 Mn |
| Sep 30, 2024 | 223.39 Mn |
| Jun 30, 2024 | 221.61 Mn |
| Mar 31, 2024 | -190.95 Mn |
| Dec 31, 2023 | 218.85 Mn |
| Sep 30, 2023 | -190.57 Mn |
| Jun 30, 2023 | -189.62 Mn |
| Mar 31, 2023 | 215.37 Mn |
| Dec 31, 2022 | 214.09 Mn |
| Sep 30, 2022 | -184.08 Mn |
| Jun 30, 2022 | 203.80 Mn |
| Mar 31, 2022 | -176.69 Mn |
| Dec 31, 2021 | 200.61 Mn |
| Sep 30, 2021 | 199.01 Mn |